Discrete Role for Cytosolic Phospholipase A2α in Platelets: Studies Using Single and Double Mutant Mice of Cytosolic and Group IIA Secretory Phospholipase A2 by Wong, Dennis A. et al.
 
J. Exp. Med. 
 

 
 The Rockefeller University Press • 0022-1007/2002/08/349/9 $5.00
Volume 196, Number 3, August 5, 2002 349–357
http://www.jem.org/cgi/doi/10.1084/jem.20011443
 
349
 
Discrete Role for Cytosolic Phospholipase A
 
2
 
  
 
in Platelets: 
Studies Using Single and Double Mutant Mice of Cytosolic 
and Group IIA Secretory Phospholipase A
 
2
 
Dennis A. Wong, Yoshihiro Kita, Naonori Uozumi, and Takao Shimizu
 
Department of Biochemistry and Molecular Biology, and Core Research and Evolutional Science and Technology, 
The University of Tokyo, Tokyo 113-0033, Japan
 
Abstract
 
Among several different types of phospholipase A
 
2
 
 (PLA
 
2
 
), cytosolic PLA
 
2 
 
(cPLA
 
2
 
)
 
  
 
and group
IIA (IIA) secretory PLA
 
2
 
 (sPLA
 
2
 
) have been studied intensively. To determine the discrete roles
 
of cPLA
 
2
 
  
 
in platelets, we generated two sets of genetically engineered mice (cPLA
 
2
 
 
 
 
 
/
 
 
 
/
sPLA
 
2
 
-IIA
 
 
 
/
 
  
 
and cPLA
 
2
 
 
 
 
 
/
 
 
 
/sPLA
 
2
 
-IIA
 
 
 
/
 
 
 
) and compared their platelet function with their
 
respective wild-type C57BL/6J mice (cPLA
 
2
 
 
 
 
 
/
 
 
 
/sPLA
 
2
 
-IIA
 
 
 
/
 
 
 
) and C3H/HeN (cPLA
 
2
 
 
 
 
 
/
 
 
 
/
sPLA
 
2
 
-IIA
 
 
 
/
 
 
 
). We found that cPLA
 
2
 
  
 
is needed for the production of the vast majority of
thromboxane (TX)A
 
2 
 
with collagen stimulation of platelets. In cPLA
 
2
 
 
 
-deficient mice, how-
ever, platelet aggregation in vitro is only fractionally decreased because small amounts of TX
produced by redundant phospholipase enzymes sufficiently preserve aggregation. In compari-
son, adenosine triphosphate activation of platelets appears wholly independent of cPLA
 
2
 
  
 
and
sPLA
 
2
 
-IIA for aggregation or the production of TX, indicating that these phospholipases are
specifically linked to collagen receptors. However, the lack of high levels of TX limiting vaso-
constriction explains the in vivo effects seen: increased bleeding times and protection from
thromboembolism. Thus, cPLA
 
2
 
  
 
plays a discrete role in the collagen-stimulated production of
TX and its inhibition has a therapeutic potential against thromboembolism, with potentially
limited bleeding expected.
Key words: knockout mice • platelet aggregation • bleeding • thromboembolism • thromboxane
 
Introduction
 
Platelets are required for hemostasis but also contribute in
the pathogenesis of thrombotic and inflammatory diseases.
A discrete therapeutic change in their properties is needed
to maintain safety. Lipid mediators generated from phos-
pholipid membranes, platelet-activating factor, or eico-
sanoids derived from released arachidonic acid (AA)
 
* 
 
are
thought to play an important role in their activation (1–4).
The inhibition of an AA modifying enzyme, cyclooxygen-
ase, by aspirin continues to be the single most successful
therapy at preventing thrombotic disease (5). Thrombox-
ane (TX)A
 
2 
 
has been most clearly linked to function with
the reports of genetic defects causing bleeding tendencies
(6–8). There are potentially multiple classes of phospholi-
pase A
 
2 
 
(PLA
 
2
 
) that may be involved in AA release:
group IIA (IIA) secretory PLA
 
2 
 
(sPLA
 
2
 
), cytosolic PLA
 
2
 
s
(cPLA
 
2
 
s), group V sPLA
 
2
 
, calcium-independent PLA
 
2
 
s, and
group X sPLA
 
2
 
 (9–13). As well as through the sequential
action of phospholipase C (PLC), diglyceride lipase, and
monoglyceride lipase, AA can be generated from phos-
phatidylinositol. However, cPLA
 
2
 
 
 
, acting primarily on
phosphatidylcholine, is thought to be the main enzyme in-
volved in AA release on the activation of platelets. The dis-
 
covery of paralogues, 
 
 
 
 and 
 
 
 
 forms of this enzyme, in addi-
tion to the previously cloned cPLA
 
2
 
 
 
 form, has added
further complexity (14–16).
Platelet exposure to matrix components such as collagen
necessitates a rapid response. In a complex multistage pro-
cess platelets change shape, degranulate, and then aggregate
(17). The binding of platelets to collagen has been reported
to involve at least two receptors. Initial binding is to an in-
tegrin, 
 
 
 
2
 
 
 
1
 
, which can bind at high sheer rates and is re-
ported to activate AA release by PLA
 
2 
 
enzymes. In vivo,
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2
 
, cytosolic phospholipase A
 
2
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2
 
, phospholipase A
 
2
 
; PLC, phospholipase C; sPLA
 
2
 
, secretory PLA
 
2
 
;
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this binding is likely followed by the subsequent binding of
collagen to glycoprotein VI (18). Other platelet activators,
thrombin, TXA
 
2
 
, ADP, and platelet-activating factor, act
through G protein–coupled receptors on the surface of
platelets. The blocking of G protein signaling may effec-
tively inhibit platelet aggregation induced by collagen in-
terfering with the accelerating effects of TXA
 
2 
 
and ADP
released after collagen binding and signaling.
The study of the enzymes involved in AA release is re-
stricted by the unavailability of highly specific inhibitors to
the various PLA
 
2
 
s. Mice lacking both cPLA
 
2
 
  
 
(engineered)
and sPLA
 
2
 
-IIA (spontaneous) were previously generated to
study the role of cPLA
 
2
 
  
 
in vivo (19, 20). Backcrossing
these mice into the C3H/HeN mice with a working
sPLA
 
2
 
-IIA gene creates a strain with only the cPLA
 
2
 
  
 
gene
inactivated. Both strains of mice were generated in our lab-
oratory and studied to question the specific role of cPLA
 
2
 
 
 
in platelet activation. In vitro studies were conducted with
the simultaneous measurement of degranulation by ATP
release and platelet aggregation through impedance allow-
ing the evaluation of the continuous effects of the loss of
these enzymes (21, 22). Bleeding times and a thromboem-
bolism model were used to study the effects in vivo.
Our results support a key role for cPLA
 
2
 
  
 
in the produc-
tion of TXA
 
2 
 
in platelets but suggest a basic redundancy in
its production from other mechanisms. We also found that
ADP or TXA
 
2 
 
activation of platelets appears independent
of cPLA
 
2
 
  
 
and likely leads to the involvement of other
PLA
 
2
 
s. In vivo studies suggest that a specific cPLA
 
2
 
  
 
inhib-
itor, in addition to an antiallergic/antiinflammatory effect
and a growth suppression effect on intestinal polyp (19, 20,
23–31), will therefore have an antivasoconstrictive effect by
dramatically reducing the amount of TXA
 
2 
 
produced.
 
Materials and Methods
 
Reagents.
 
1 mg/ml equine type I collagen, 1 mM ADP, ATP
standard, and Chrono-lume reagent, a bioluminescent luciferase
mixture, were purchased from Chrono-log Co. Before use,
U46619, a TX receptor agonist in methyl acetate, was evaporated
and diluted in PBS (Cayman Chemical). SQ29548, a highly spe-
cific TXA
 
2 
 
receptor antagonist, was dissolved in ethanol for stor-
age and then evaporated and diluted in PBS just before experi-
ments were performed (Cayman Chemical). Indomethacin
(Sigma-Aldrich) was dissolved in 0.1 M sodium bicarbonate be-
fore use. 12(S)-hydroxyeicosatetraenoic acid (HETE) was pur-
chased from Cayman Chemical.
 
Mice.
 
Inbred mice were purchased from Central Laboratories
for Experimental Animals Japan. As previously described (19), the
cPLA
 
2
 
  
 
gene was disrupted by replacing part of an internal exon
with a PGK-neo cassette. The mice generated (F2 of C57BL/6J
and 129/Ola) were cPLA
 
2
 
 
 
    
 
and were also discovered to be
congenitally defective in sPLA
 
2
 
-IIA due to a frameshift mutation
in the sPLA
 
2
 
-IIA gene (32, 33). These mice were backcrossed to
the C3H/HeN strain, which were gene sequenced to ensure the
presence of a functional sPLA
 
2
 
-IIA gene. Eighth and ninth gener-
ation backcrossed C3H/HeN mice were used. Twelfth genera-
tion backcrossed C57BL/6J mice were also used in the experi-
ments. All mice were genotyped by a PCR method as previously
described (19).
 
In Vitro Platelet Responses.
 
20–48-wk-old littermate back-
crossed mice matched for sex were studied in pairs (cPLA
 
2
 
 
 
 
 
/
 
 
 
,
cPLA
 
2
 
 
 
 
 
/
 
 
 
) to exclude any potential bias. Mice were anesthe-
tized with 25 mg/kg pentobarbital and 25 mg/kg ketamine, and
 
 
 
1 ml of whole blood was immediately collected in 0.35% (wt/
vol) sodium citrate after cardiac puncture. After 30 min, 100 
 
 
 
l
whole blood was diluted with 800 
 
 
 
l normal saline and 100 
 
 
 
l
Chromo-lume reagent. Aggregation as measured by change in
impedance and ATP release from dense granules were moni-
tored continuously by luminometry (Chrono-Log Co.). To al-
low for comparison between the experiments, aggregation/im-
pedance was adjusted to measure a set change in resistance by
changing the baseline and height of a standard impulse. A 2-nM
dose of ATP was added at the end of each measurement to stan-
dardize ATP. If the baseline measurement of ATP indicated the
presence of marked platelet degranulation during cardiac punc-
ture, the experiment was terminated. Continuous measure-
ments were made electronically at every 25 ms, but summarized
to the second for analysis. Reagents were added only after 2 min
of a flat baseline in both measurements and the ATP level was
 
 
 
0.1 nM.
 
TXA
 
2
 
 Assay.
 
After 9 min of reaction, 100 
 
 
 
l of the aliquot
was placed on ice. Samples were then spun at 1,000 
 
g
 
 for 5 min
and the supernatant was frozen at 
 
 
 
70
 
 
 
C until analysis. For each
mouse, 50
 
  
 
l of the sample was saved to measure the baseline
levels before stimulus. TXB
 
2
 
, a nonenzymic hydrolyzed product
of TXA
 
2
 
, was measured by an enzyme immunoassay kit (Cayman
Chemical).
 
12-HETE Assay.
 
Quantification of 12-HETE was per-
formed by reversed phase HPLC (system GOLD; Beckman
Coulter) using a solvent of acetonitrile/methanol/water/acetic
acid, 350:150:250:1 (2, 34). Flow rate was 1 ml/min and eluent
was monitored at 235 nm. Blood was collected from incisions on
femoral vessels of anesthetized mice (25 mg/kg pentobarbital and
25 mg/kg ketamine). After 30 min of incubation at room tem-
perature to allow clotting, serum samples were collected by cen-
trifugation at 500 
 
g for 5 min. Samples were extracted with eth-
ylacetate after acidification to a pH of  5.0 with 0.5 vol of 0.1%
formic acid, dried on a centrifuge concentrator, dissolved in the
HPLC solvent, and analyzed. To normalize the extraction rate,
0.5 nmol 12(S)-HETE was added to selected samples before ex-
traction and the difference of the area was calculated.
Bleeding Time. Adult mice were restrained in the upright po-
sition and the tail was cut 2–3 mm from the tip. The tail was then
immersed in saline at 37 C and the bleeding time was defined as
the time point at which all visible signs of bleeding from the inci-
sion had stopped, or at 10 min (35). Because of a significant dif-
ference between males and females in knockout C3H/HeN, only
females were used in later studies. 10 mg/kg indomethacin was
injected intraperitoneally 1 h before the bleeding times were
tested in age-matched female mice.
Thromboembolism Test. In mice anesthetized with 80 mg/kg
sodium pentobarbital, a collagen–ADP mixture (4 ml/kg of a sa-
line-based solution containing 250 mg/ml collagen and 200  M
ADP) was injected into the jugular vein. Survival was evaluated
1 h after injection (36, 37). The dose was pretested to ensure
100% killing of wild-type mice (38). One pair of mice were killed
and intubated 2 min after injection. 4% formalin in PBS was in-
jected into the lung, and then the heart and lung were dissected
together and placed in 10% formalin in PBS. Serial sections were
cut and stained with hematoxylin and eosin for examination. A
blindfolded investigator counted 20 areas at 400  for each mouse
to determine the percentage of clotted vessels.351 Wong et al.
Statistics. All values are expressed as mean   SD unless stated
otherwise. Two-tailed t tests were used to test the significance
on continuous data and multiple regression was used to calculate
the P-values on nominal data and in multivariable analysis
(Quattro Pro).
Results
Degranulation and Aggregation to Collagen. C3H/HeN
cPLA2  /  sPLA2-IIA /  mice show a delay in degranula-
tion as measured by ATP release in response to collagen
(Fig. 1 a). This accompanies a more concave impedance
curve, indicating a slowing in the acceleration phase of
platelet aggregation. Aggregation achieved at 9 min was
preserved in cPLA2  /  platelets. The time to achieve
peak ATP release (Fig. 2, left, P   0.013) and the time to
reach 50% of aggregation achieved within 9 min (Fig. 1 a;
cPLA2  / , 227   43.7 s vs. cPLA2  / , 268   42.8 s;
P   0.042) is significantly delayed. Focusing on the first 20 s
of the reaction, it appears that the loss of cPLA2  starts to
have an effect on the rate of degranulation at about the 20-s
mark (Fig. 1 a). Compared to the changes in response to
collagen, the reaction to U46619, a TX agonist, and ADP,
both of which work through G protein–mediated recep-
tors, appears to be unchanged (Fig. 1, b and c). C57BL/6J
cPLA2  /  sPLA2-IIA /  mice appear to have the same
shaped curve as C3H/HeN cPLA2  /   sPLA2-IIA / 
mice (Fig. 1 d). C57BL/6J cPLA2  /  sPLA2-IIA /  mice
also show a significant delay in the degranulation peak
(Fig. 2), and a more concave aggregation curve. The times
to reach 50% of aggregation were as follows: cPLA2  / 
sPLA2-IIA / , 178    14.6 s versus cPLA2  /  sPLA2-
IIA / , 255   67.0 s; P   0.021. An indirect comparison
of the changes between C3H/HeN and C57BL/6J mice
using time to peak ATP can be attempted. There is an in-
dication of an additional step delay due to the additional
loss of sPLA2 when compared with cPLA2  loss alone (Fig.
1, a and d, and Fig. 2). The effect of other factors cannot
fully be excluded due to the differences in the mouse
strains used.
TX Levels. Compared to the small difference in de-
granulation and aggregation in vitro (Figs. 1 and 2), there
is a marked, significant decrease in the amount of TXB2
production as detected after collagen activation between
cPLA2  /  and cPLA2  /  mice in both C3H/HeN and
C57BL/6J strains (Fig. 3). The absolute difference in the
C57BL/6J mice is larger (3.5 vs. 1.4 ng/ml), which is con-
sistent with the ATP and aggregation curves. With the in-
crease in TXA2 upon stimulation, it is also clear that a lim-
ited amount of AA is being released in both strains of
cPLA2  /  mice, indicating the presence of another PLA2
or an alternative AA-generating pathway. In accord with
the aggregation and degranulation data (Fig. 1), there is
little difference in TXB2 production in response to ADP
between C3H/HeN wild-type and cPLA2 -deficient
Figure 1. Effect of cPLA2  on platelet activation.
ATP release (left axis) as monitored by luciferase activ-
ity is seen on the top of each graph. The first 20 s of
the reaction is magnified above. Platelet aggregation
(right axis) as measured by impedance is at the bottom.
In each case, averaged data from wild-type littermates
( / ) are paired with sex-matched cPLA2 -deficient
mice ( / ). (a) C3H/HeN mice platelet reaction to
collagen (n   9). (b) C3H/HeN reaction to U46619
(n   7). (c) C3H/HeN reaction to ADP (n   6). (d)
C57BL/6J reaction to collagen (n   4).
Figure 2. Time to peak ATP after collagen. The mean of individual
times to maximum ATP level of each mouse is used in Figs. 1 and 4
plotted by strain, cPLA2  status, and TXA2 antagonist, SQ29548. Error
bars are SD above the mean and P-values stand for significant differences.352 Discrete Role for Cytosolic Phospholipase A2  in Platelets
mice, suggesting a cPLA2 -independent mechanism for
TXA2 production with ADP as a stimulus. Similarly in
C57BL/6J platelets stimulated with ADP, there was little
difference in ATP release and aggregation (unpublished
data), and TXB2. Therefore, an AA-releasing mechanism,
possibly another PLA2(s) or PLC–diglyceride lipase system
independent of both cPLA2  and sPLA2-IIA, is present in
platelets upon the stimulation of G protein–coupled re-
ceptor ligands.
Effect of a Specific TX Antagonist. To confirm the pres-
ence of additional specific TXA2  activity generated by
cPLA2 /sPLA2-IIA, a specific TXA2 receptor antagonist,
SQ29548, was used (39). Platelet activation appears both
TXA2-dependent and -independent, as SQ29548 was un-
able to completely block activation in all cases (Fig. 4).
Upon examining the TXA2-dependent component, the re-
sults on C3H/HeN cPLA2
 /   sPLA2-IIA /   mice and
C57BL/6J cPLA2
 /  sPLA2-IIA /  in Fig. 4, c and d, con-
firm the presence of an alternative redundant enzyme(s) be-
cause a persistent inhibiting effect is seen in both mouse
strains. In addition, SQ29548 inhibited degranulation and
aggregation slightly more in the C57BL/6J mice, where
the sPLA2-IIA enzyme activity is missing, than in the
C3H/HeN mice (Fig. 4, compare a and c, and b and d). A
hint of the additional effect of sPLA2-IIA is also seen when
all the times to peak ATP results are graphed (Fig. 2).
There appears to be a stepwise delay as successive enzymes
are lost or TXA2 activity is blocked. Statistically, however,
multiple regression of the factors that influence time to
peak ATP demonstrates an independent significant effect of
the loss of cPLA2  and the inhibitor SQ29548. The effect
of the mice strain (the loss of sPLA2-IIA) did not reach sta-
tistical significance. Therefore, in these studies we can only
conclude that cPLA2  /  platelets have an alternative AA-
generating mechanism to cPLA2  and sPLA2-IIA. How-
ever, it is interesting to see that as expected, the effect of
the inhibitor is smaller in the C57BL/6J strain with only a
possible delay in the initiation of the reaction seen (Fig. 4, c
and d). There is also a suggestion that the inhibitor effect of
SQ29548 occurs earlier than at 20 s when compared with
the effect of the loss of cPLA2  as seen in Fig. 1.
Serum 12-HETE Levels. Next, we determined the con-
tribution of cPLA2  on the production of 12-HETE, an-
other AA metabolite. As shown in Fig. 5 a, elution of 12-
HETE was observed at 11.9 min on HPLC analysis. The
absorbance spectrum was indistinguishable from authentic
12(S)-HETE, and coelution was also observed when they
were mixed (not depicted). As shown in Fig. 5 b, the cal-
culated concentration of 12-HETE in serum from C3H/
HeN cPLA2  /  adult female mice was 0.72   0.28  M
(n   14), significantly lower than cPLA2  /  (2.4   1.5
 M; n   13; P   0.001) and cPLA2  /  (1.8   0.83  M;
n   15; P   0.05). A similar significant difference was ob-
served for C57BL/6J adult male mice: cPLA2  /  (3.2  
1.6  M; n   6) versus cPLA2  /  (0.44   0.25  M; n  
6; P   0.01; Fig. 5 b).
Figure 3. TXB2 produced after platelet stimulation. Mean change in
TXB2 levels of mice pairs in Fig. 1. Open columns, cPLA2  /  mice;
shaded columns, cPLA2  /  mice. Because of the log scale, actual mean is
given above the columns, error bars are SD above the mean, and P-values
stand for significant differences.
Figure 4. Effect of a TXA2  receptor antagonist,
SQ29548, on platelet activation. ATP release (left axis)
as monitored by luciferase activity is seen on the top of
each graph. The first 20 s of the reaction is magnified
above. Platelet aggregation (right axis) as measured by
impedance is at the bottom. In each case, responses to
collagen are compared with and without SQ29548
from pooled data from wild-type ( / ) or cPLA2 -
deficient mice ( / ). (a) C3H/HeN cPLA2  /  mice
(n   3), (b) C57BL/6J cPLA2  /  mice (n   3), (c)
C3H/HeN cPLA2  /  mice (n   2), and (d) C57BL/6J
cPLA2  /  mice (n   2).353 Wong et al.
Marked Changes in Bleeding Time. Compared to the in
vitro aggregation results, the differences in bleeding time
correlate with TXB2 levels. Bleeding times in both C3H/
HeN and C57BL/6J mice were significantly increased (Fig.
6 a). However, because of a marked difference between
male and female mice (unpublished data), only female mice
were used for comparison between strains and interven-
tions. Bleeding times, like the in vitro aggregation results,
show that the cPLA2  /  C57BL/6J mice have longer
bleeding times than C3H/HeN females and cyclooxygen-
ase inhibition with indomethacin leads to a similar increase
in bleeding time.
Protective Effect of cPLA2  Loss on Thromboembolism. In
the thromboembolism test there was an increase in survival
that is significant in cPLA2  /  mice (Fig. 6 b). After the
dissection of the heart and lungs together, the cPLA2  / 
lungs were of a much darker red than the cPLA2  / , sug-
gesting increased vasoconstriction in the presence of
cPLA2 . However, both were engorged with blood com-
pared with normal lungs due to clots. Blinded counts show
an equal percent of clotted vessels in the wild type and
knockout (cPLA2  / , 76% vs. cPLA2  / , 82%). The
percentage is similar to previous studies (37). In cPLA2  / 
mice, small vessels were mostly clotted with evidence of ar-
terial constriction and platelet clots in large arteries (Fig. 6
c, top and bottom right). In cPLA2  /  mice, perhaps be-
cause of the lack of TXA2-induced arterial constriction,
platelet clots were allowed to reach larger collecting veins
(Fig. 6 c, top and bottom left). The large number of platelet
clots seen in knockout mice indicates that platelets are able
to aggregate well, as suggested by the in vitro studies. The
collection of clots in the venous side of the pulmonary sys-
tem in mice lacking cPLA2  appears to be more forgiving
than clotting of the arterial side of the pulmonary artery
system, which explains the reduction in mortality.
Discussion
By using platelets of two sets of genetically engineered
mice, we found that cPLA2  plays a critical role in TXA2
production but a relatively redundant autocrine role in
platelet aggregation due to an alternative AA-releasing
mechanism. The lack of cPLA2  leads to a dramatic loss of
Figure 5. Serum 12-HETE content. (a)
Representative HPLC chart.  / , a
cPLA2  /   mouse (3.6  M);   / ; a
cPLA2  /  mouse (1.0  M). (b) Mean lev-
els of 12-HETE in serum. Open col-
umns, cPLA2  /  mice; hatched column,
cPLA2  /  mice; shaded columns,
cPLA2  /  mice. Error bars are SD above
the mean and P-values stand for significant
differences.
Figure 6. In vivo effects of cPLA2 . (a) Bleeding time. Open columns,
cPLA2  /  female mice; shaded columns, cPLA2  /  female mice. C3H/
HeN mice (cPLA2  / ,  n     15; cPLA2  / ,  n     10), C57BL/6J
(cPLA2  / , n   7, wild-type nonlittermates; cPLA2  / , n   7), and
C3H/HeN mice treated with indomethacin (six mice in each group strat-
ified by bleeding time). Error bars are SD above the mean and P-values
for significant differences between cPLA2  /  and cPLA2  /  are shown
in each case. (b) Death in thromboembolism test of C3H/HeN littermate
mice matched for sex and eight or ninth generation backcrossed. (c)
Lung histology of cPLA2  /  and cPLA2  /  hematoxylin and eosin
stain. In cPLA2  /  mice at a low magnification (top) there are multiple
platelet clots seen, causing red blood cell congestion in small and me-
dium vessels. At a higher magnification (bottom), draining veins can be
seen with platelet clots. In cPLA2  /  mice at a low magnification
(top), smaller vessels appear to be clotted. At a higher magnification a
muscular artery is seen with platelet clots. B, bronchi; LN, lymph node.
Bars, 100  M.354 Discrete Role for Cytosolic Phospholipase A2  in Platelets
TXA2 production from collagen-activated mouse platelets
in vitro. This loss contrasts to a small but significant delay
in ATP release and a small but significant loss in the accel-
eration of platelet aggregation. The TXA2 results, how-
ever, correlate well with a marked increase in bleeding
time in mice lacking cPLA2 . This discrepancy is best ex-
plained if the vasoconstrictive effect of TXA2 is consid-
ered. The test of bleeding time transects large veins and ar-
teries in the mice tail. The veins, in particular, could be
seen bleeding profusely in some cPLA2  /  males where
the diameter of the tail is considerably larger than that of
the female, whereas in cPLA2  /  mice bleeding could
stop abruptly at 60–90 s due to vasoconstriction. The need
for more vasoconstriction normally induced by TXA2
would help explain the difference in bleeding time be-
tween the cPLA2  /  C3H/HeN males (large diameter
vessels) and females (smaller diameter vessels; unpublished
data). This explanation fits well with the biological effects
of TXA2 inhibition with aspirin. Acute vascular syndromes
are being prevented but with well-preserved aggregation
at low intermittent dosing, i.e., inhibiting much, but not
all, of the TXA2. Small amounts of TXA2 might be re-
quired early by platelets to activate themselves effectively,
whereas the larger amounts produced mostly by cPLA2 
are intended for vasoconstriction. All of the current results
support a dual function for TXA2 and a discrete role for
cPLA2  in mouse platelets. (a) There are low levels of
TXA2 in both strains of knockout mice and therefore rela-
tively well-preserved aggregation. (b) ADP, TXA2 (Fig. 1,
b and c, and Fig. 3), and probably other G protein–cou-
pled receptor ligands, independent of cPLA2 , stimulate
TXA2 production, suggesting a redundant source of low
level AA release. (c) In both strains of mice, a specific
TXA2 antagonist appeared to extend the delay in aggrega-
tion in proportion to the level of TXA2 expected to be
generated and also appeared to have an earlier effect. (d)
There is a stepwise increase in bleeding times due to the
blocking of successive enzyme loss between cPLA2  / 
and cPLA2  / /sPLA2-IIA /  mice, similar to the in vitro
aggregation pattern. (e) During thromboembolism, the
preservation of the ability to form platelet clots in
cPLA2  /  mice with decreased lethality is probably due
to the modification of vascular effects.
These results suggest that although cPLA2  is responsible
for the vast majority of TXA2 production in activated
platelets after collagen stimulation, there are redundant en-
zymes in platelets that can maintain basic platelet aggrega-
tion with relatively small amounts of TXA2. The loss of this
baseline autocrine TXA2 effect leads to a more profound
loss of platelet function. At least two independent mecha-
nisms of TXA2 production are apparent in mouse platelets
with different PLA2 enzymes, production levels and physi-
ological effects. Additional support for this is the log fold
difference in the dose of TXA2 agonist required for smooth
muscle contraction and platelet activation, even though the
TXA2 receptors appear to be the same (40, 41). There is
mounting evidence for the dual role, an intracellular role
and an intercellular/extracellular role, for any given lipid
mediator (42). The cPLA2  enzyme appears to play a criti-
cal part in generating lipid mediators for extracellular roles
in platelets. It is also possible that platelets can utilize AA
provided by serum lipids and neighboring cells.
The loss of cPLA2  also appears to be important in the
release of AA needed to produce other lipid mediators that
may augment platelet aggregation/TXA2 production (2).
The loss of 12-HETE production evident in mice without
cPLA2  provides another mechanism by which the absence
of cPLA2  could act. The amount of 12-HETE depen-
dence on cPLA2  during aggregation may also apply to 12-
lipoxygenase activity in other cell types and could contrib-
ute to the antiatherosclerosis/antiangiogenesis effect of
cPLA2  inhibition (43–46).
The delay in   granule release, as reflected in ATP, asso-
ciates with and precedes the delay in aggregation and there-
fore may play a mechanistic role. There appears to be a
more generalized delay in degranulation in cells missing
cPLA2  (25, 26). The delay in degranulation is not present
with a TX agonist or ADP and is reproduced with a spe-
cific antagonist, which suggests that a reduction in the pace
of the reaction is the only explanation needed for the delay
in ATP release in these studies.
Rather than representative data, electronic summarized
graphs are chosen in our experiments to block out the mul-
tiple factors that can influence platelet studies in mice.
Variations in activation and platelet numbers during cardiac
puncture cannot be easily standardized. As an alternative to
the current approach, dilution of whole blood to a standard
platelet count would add the variation caused by the dilu-
tion of plasma factors. During preliminary studies on third
generation mice, small differences in platelet response were
seen. Therefore, steps such as blocking for age and sex
were used to decrease all other possible sources of variation.
The presence of similar results in both strains of mice and
the complimentary findings with the use of a specific an-
tagonist to TXA2 validates the approach. In vitro platelet
data must, however, be viewed with some skepticism (47).
In mice where careful controlled collection of blood is dif-
ficult, special care to correlate in vitro and in vivo experi-
ments is needed. Although the use of different strains of
mice help strengthen the generalization of the results, the
comparisons between the two strains have to be carefully
interpreted. The base levels of TXA2 and ATP levels be-
tween C3H/HeN and C57BL/6J in response to collagen
are different. Without a C57BL/6J mouse with a functional
sPLA2-IIA as a control, conclusions on the role of this en-
zyme in platelets cannot be certain. The addition, however,
of studies using the C57BL/6J does show that sPLA2-IIA is
not the only alternative AA-generating enzyme to cPLA2 
in platelets.
Previous platelet studies with engineered mice put these
new findings in context. Mice with G q deficiency have
severe loss of platelet functions with little evidence for re-
dundant processes for this key protein (48). In knocking
out P2Y1, an ADP receptor, evidence was found for a sec-
ond, partially redundant receptor that was recently cloned
(36, 49, 50). The surprise finding, the disruption of CD39,355 Wong et al.
which is an ATP diphosphohydrolase, was an inhibition of
platelet aggregation (51). AA released by PLA2s may also
be acted upon by 12-lipoxygenase to form 12-HETE.
Knockout studies suggest that this might be a factor that
plays a unique role in ADP-stimulated platelets (2). In
TXA2 receptor knockout mice, findings very consistent
with the current results were found (1). The bleeding times
were also prolonged with the loss of TXA2 receptor, which
contrasted with human receptor deficiency. However, the
test for bleeding time in humans and that used in mice is
very different. The vasoconstriction caused by TXA2 may
have a significant effect on the bleeding times measured on
mice tails compared to the human tests where aggregation
in small skin vessels is tested. A delay in collagen activation
compared to ADP activation was noted similarly to our pa-
per. The current, more sensitive studies confirm a delay in
the initiation of aggregation but also suggest that a stepwise
loss of TXA2 has effects on aggregation, with the complete
loss of all TXA2 having a more pronounced effect on ag-
gregation. The current results cannot be directly compared
with those of the TXA2 receptor knockout because of dif-
ferent methodologies. It cannot be excluded, however,
that an additional mechanism, which is TXA2 receptor in-
dependent, is present. Studies involving multiple knock-
outs and specific inhibitors are needed to take the entire
process apart.
The use of specific inhibitors to intracellular signaling
proteins and knockout studies has provided some insights
into how cPLA2  might be regulated in platelets. First, G
protein–coupled receptors to ADP, thrombin and TXA2,
appear to work through Gq proteins and activate PLC  s
(48, 52, 53). Second, the recently cloned glycoprotein VI
appears to require coactivation of the integrin  2 1 to ini-
tiate a reaction. That reaction involves lyn and fyn Src fam-
ily kinases that affect p72 Syk, leading to a pathway
through SLP-76 to PLC 2 (17, 54–57). Third, the signal-
ing though  2 1 involves actin polymerization and proba-
bly involves the activation of an Src kinase leading to a mi-
togen-activated protein kinase–dependent cPLA2 activation
(58–61). Therefore, platelet activation appears to involve at
least three different pathways that interact with one an-
other. cPLA2  activation would appear to be related to the
pathway through integrin  2 1 and an alternative mecha-
nism, most likely another PLA2(s), through G protein–cou-
pled receptors (ADP or TXA2, etc.). The picture that
emerges is that platelet activation is a complex multichan-
neled process involving multiple surface receptors and in-
tracellular signaling pathways that mostly behave in vivo
with increasing intensity. The loss of any particular protein
may thus have a broad or distinct effect depending on its
unique placement in a complex scheme.
Although these results in mouse platelets provide insights
into human platelet function, in vivo use of specific inhibi-
tors of cPLA2  (62) and sPLA2-IIA are needed to confirm
these results in humans.
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